Last reviewed · How we verify

NCT07087834

Men's Perceptions, Attitudes, and Knowledge Levels Toward Cancer Screening

Active, enrolled NA Last updated 21 January 2026
What this trial tests

NA trial testing CASEM (Cancer Screenings Education for Men) in Men's Health Screening in 78 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 September 2025
Primary endpoint
30 September 2025
30 April 2026

Quick facts

Lead sponsorPamukkale University
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment78
Start date1 September 2025
Primary completion30 September 2025
Estimated completion30 April 2026
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Pamukkale University

Who can join

30 and older, male only, with Men's Health Screening or Cancer Screening. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Countries are establishing national and international cancer control programs in response to cancer, which has become a global problem. Therefore, cancer is a disease that can be combated not only through investments in treatment, but also through efforts focused on prevention and early diagnosis. According to GLOBOCAN 2022 data, more than 51% of all cancer cases worldwide occur in men. The three most common types of cancer in men are lung cancer, prostate cancer, and colorectal cancer. Increasing awareness, attitudes, and knowledge levels regarding cancer screenings, especially for preventable diseases, will increase participation in screening programs. Increased knowledge levels will translate into positive health behaviors. This study will be conducted as a randomized controlled trial to determine the effect of the Cancer Screenings Education for Men (CASEM) intervention on men's perceptions, attitudes, and knowledge regarding cancer screening programs. Research data will be collected at a public institution between September 2025 and September 2026. The study sample will consist of a total of 78 male individuals, including 39 experimental and 39 control groups that meet the inclusion criteria. Male individuals will be assigned to the experimental and control groups using stratified randomization. The Individual Identification Form, Cancer Screening Perception Scale, Cancer Screening Attitude Scale, and Cancer Screening Knowledge Scale will be used. IBM SPSS 29.0 software will be used to analyze the data obtained from the study. This study will be an important one that addresses Turkey's future vision within the scope of the Twelfth Development Plans and supports the goals and policy measures of the development plan. In addition, our study serves the Sustainable Development Goals, which are among the most important global goals in the context of sustainability. It is expected to have implications for health practices and planning.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Pamukkale University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07087834.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing